Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial

Authors not listed

Prince of Wales Hospital, Shatin, Hong Kong · 2024

Abstract

The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-24 MST

Cite this

APA
Anonymous. (2024). RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial. <em>Prince of Wales Hospital, Shatin, Hong Kong</em>. https://clinicaltrials.gov/study/NCT06643780
Vancouver
Anonymous. RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial. Prince of Wales Hospital, Shatin, Hong Kong. 2024.
BibTeX
@misc{anon2024RANKli, title = {RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial}, author = {Anonymous}, journal = {Prince of Wales Hospital, Shatin, Hong Kong}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings